Bruker and RECIPE are pioneering the high-throughput ‘chrom-free’ ClinDART triple-quad MS platform for robust and cost-effective therapeutic drug monitoring assays Bruker Corporation (NASDAQ ...

BILLERICA, Mass., April 11, 2025--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $ ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Recursion Pharmaceuticals (RXRX – Research Report) and Bruker (BRKR – Research Report).

The novel 1.3 GHz magnet extends Bruker’s innovative LTS-HTS hybrid magnet architecture. Despite higher field, the 1.3 GHz magnet maintains the same physical dimensions and cryogen consumption ...

Across the recent three months, 6 analysts have shared their insights on Bruker BRKR, expressing a variety of opinions spanning from bullish to bearish. The table below offers a condensed view of ...

Bruker has entered into a strategic collaboration for NGS bioinformatics applications in microbiology and infectious disease testing with Ridom GmbH, based in Muenster, Germany. Ridom´s NGS ...

Barclays analyst Luke Sergott maintained a Buy rating on Bruker (BRKR – Research Report) today and set a price target of $50.00. The company’s shares closed last Friday at $38.76. Discover ...

At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the successful development and testing of the ...

At the ESCMID Global 2025 conference, Bruker´s Microbiology and Infection Diagnostics division is announcing the expansion of its microbiology solutions into Next-Generation Sequencing (NGS ...